CancerDrs

Colorectal Cancer clinical trials in Michigan

62 actively recruiting colorectal cancer trials at 54 sites across Michigan.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 2, Phase 3 Recruiting Academic/Other

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.

Sponsor: NRG Oncology
NCT ID: NCT05174169
Sites in Michigan:
  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
  • University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
  • Bronson Battle Creek — Battle Creek, Michigan
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
  • Trinity Health Medical Center - Brighton — Brighton, Michigan
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors

This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that al…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT07018869
Sites in Michigan:
  • MyMichigan Medical Center Gratiot — Alma, Michigan
  • MyMichigan Medical Center Alpena — Alpena, Michigan
  • Trinity Health IHA - Obstetrics and Gynecology West Arbor — Ann Arbor, Michigan
  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
  • Bronson Battle Creek — Battle Creek, Michigan
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy …

Sponsor: Pfizer
NCT ID: NCT07222800
Sites in Michigan:
  • The Cancer & Hematology Centers — Big Rapids, Michigan
  • The Cancer & Hematology Centers — Grand Rapids, Michigan
  • The Cancer & Hematology Centers — Grand Rapids, Michigan
  • The Cancer & Hematology Centers — Holland, Michigan
  • The Cancer & Hematology Centers — Norton Shores, Michigan
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limit…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06205485
Sites in Michigan:
  • Henry Ford Cancer Institute-Downriver — Brownstown, Michigan
  • Henry Ford Macomb Hospital-Clinton Township — Clinton Township, Michigan
  • Henry Ford Medical Center-Fairlane — Dearborn, Michigan
  • Henry Ford Hospital — Detroit, Michigan
  • Corewell Health Grand Rapids Hospitals - Butterworth Hospital — Grand Rapids, Michigan
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fl…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06750094
Sites in Michigan:
  • University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
  • Henry Ford Hospital — Detroit, Michigan
  • Cancer And Hematology Centers of Western Michigan PC — Grand Rapids, Michigan
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the li…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT05863195
Sites in Michigan:
  • University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
  • Corewell Health Grand Rapids Hospitals - Butterworth Hospital — Grand Rapids, Michigan
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevaci…

Sponsor: Amgen
NCT ID: NCT06252649
Sites in Michigan:
  • Henry Ford Health System — Detroit, Michigan
  • Cancer and Hematology Centers of Western Michigan — Grand Rapids, Michigan
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

The Cancer of the Pancreas Screening-5 CAPS5)Study

Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.

Sponsor: Johns Hopkins University
NCT ID: NCT02000089
Sites in Michigan:
  • University of Michigan — Ann Arbor, Michigan
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…

Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Michigan:
  • Karmanos Cancer Institute — Detroit, Michigan
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Safely Optimizing Body Weight With TCMCB07 in Patients With Newly Diagnosed Colorectal Cancer Undergoing Chemotherapy

This is a randomized, double-blind, placebo-controlled study of B07, administered daily by subcutaneous (SC) injection, in up to 120 patients with newly diagnosed locally advanced, unresectable or metastatic colorectal cancer. This study w…

Sponsor: Endevica Bio
NCT ID: NCT06937177
Sites in Michigan:
  • Investigative Site — Detroit, Michigan
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care (SOC) given al…

Sponsor: AbbVie
NCT ID: NCT07023289
Sites in Michigan:
  • University of Michigan Health System - Ann Arbor /ID# 273511 — Ann Arbor, Michigan
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.

Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Michigan:
  • Henry Ford Cancer — Detroit, Michigan
  • START Midwest — Grand Rapids, Michigan
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ …

Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06695845
Sites in Michigan:
  • Barbara Ann Karmanos Cancer Institute — Detroit, Michigan
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it…

Sponsor: Bayer
NCT ID: NCT06760819
Sites in Michigan:
  • Brigette Harris Cancer Pavilion at Henry Ford Cancer Center - Detroit — Detroit, Michigan
  • Profound Research -OMG - TriAtria Cancer Center — Farmington Hills, Michigan
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …

Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in Michigan:
  • South Texas Accelerated Research Therapeutics (START) Midwest — Grand Rapids, Michigan
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of IBI363 in Subjects with Advanced Solid Malignancies

This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.

Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
NCT ID: NCT06281678
Sites in Michigan:
  • Michigan Hematology & Oncology Consultants - MedOnc Dearborn — Dearborn, Michigan
  • Michigan Hematology & Oncology Consultants - MedOnc Troy — Troy, Michigan
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors. GEJ is where the food pipe (esophagus) joins the stomach…

Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07488676
Sites in Michigan:
  • START Midwest — Grand Rapids, Michigan
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2). The study population i…

Sponsor: LigaChem Biosciences, Inc.
NCT ID: NCT05941507
Sites in Michigan:
  • University of Michigan — Ann Arbor, Michigan
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer

This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity) and imaging time window of 64Cu-LNTH-1363S, and to compare its i…

Sponsor: Lantheus Medical Imaging
NCT ID: NCT06298916
Sites in Michigan:
  • BAMF Health, Inc. — Grand Rapids, Michigan
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

A Phase 1/2a Dose Escalation and Expansion Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients with Relapsed/Refractory, Locally Advanced Inoper…

Sponsor: Radiopharm Theranostics, Ltd
NCT ID: NCT07189871
Sites in Michigan:
  • BAMF Health — Grand Rapids, Michigan
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat. The study will …

Sponsor: GlaxoSmithKline
NCT ID: NCT07213609
Sites in Michigan:
  • GSK Investigational Site — Detroit, Michigan
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Watchful Waiting for Complete Responders to Therapy in Rectal Cancer

The purpose of this project is to determine if in a selected group of patients, at higher risk of wound dehiscence and other complications, treatment by local excision and management by a "watchful waiting" or an initial "non-operative man…

Sponsor: Henry Ford Health System
NCT ID: NCT05526079
Sites in Michigan:
  • Ascension St. John Hospital — Detroit, Michigan
View on ClinicalTrials.gov →

Showing 25 of 62 trials with sites in Michigan. See all colorectal cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-06-15